Growth hormone therapy can add meaningful height to children and adolescents who are still growing, but it does nothing for adults whose growth plates have already fused. The distinction hinges entirely on timing: the cartilage zones at the ends of long bones, called growth plates, are the only tissue through which bones can lengthen. Once those plates close, which happens during or shortly after puberty, no amount of growth hormone will make a person taller. For children treated before that window closes, the gains vary widely depending on why they are short, how early treatment starts, and how long it continues.
How Growth Hormone Actually Lengthens Bones
Long bones grow from specialized cartilage cells (chondrocytes) that sit inside the growth plates near each end of the bone. Growth hormone stimulates these cells to multiply and stack up, thickening the cartilage layer. That thicker layer then gradually converts to bone, adding length. Research on this process showed that growth hormone increases the thickness of growth zones by driving chondrocyte proliferation, which is the core mechanism behind longitudinal bone growth.1Oxford Academic. Mechanism of the Stimulatory Effect of Growth Hormone on Longitudinal Bone Growth
Growth hormone does not act alone. It triggers the liver and local tissues to produce insulin-like growth factor 1 (IGF-1), which does much of the hands-on work at the growth plate. The interplay between growth hormone, IGF-1, and sex hormones (especially estrogen) determines how fast you grow and when you stop. During puberty, rising estrogen levels in both boys and girls accelerate the senescence of the growth plate. Estrogen speeds up the depletion of chondrocytes, and once their proliferative capacity is exhausted, the growth plate fuses into solid bone.2PubMed. Effects of estrogen on growth plate senescence and epiphyseal fusion This is why the pubertal growth spurt is a double-edged sword: sex hormones working alongside growth hormone produce rapid gains in height, but they also set the clock ticking toward permanent closure.3Endocrine Reviews. Systemic and Local Regulation of the Growth Plate
Why It Will Not Work After Your Growth Plates Close
Once the growth plates fuse, bones can no longer lengthen from the inside out. Adults who take growth hormone may see changes in body composition, such as less fat and more lean mass, but they will not get taller. The fusion is irreversible. A simple hand or wrist X-ray (a bone age study) is typically used to check whether growth plates are still open, and this is one of the first steps any endocrinologist takes before considering growth hormone therapy. If your bone age shows fused plates, the conversation about height is over.
This reality has not stopped a thriving online market in growth hormone supplements and injections aimed at adults who want to be taller. Those products cannot deliver on that promise. The biological prerequisite, active growth plates, is non-negotiable.
Results for Children With Growth Hormone Deficiency
Children whose pituitary glands do not produce enough growth hormone are the group with the clearest medical need and the most straightforward response to treatment. Without treatment, these children fall progressively behind their peers in height. With daily growth hormone injections started in childhood, they can close much of that gap, though few reach the height they would have achieved if their pituitary had functioned normally.
A study of 46 children treated for growth hormone deficiency found a mean final height of about 1.1 standard deviations below average, compared to a target height (based on parental height) of about 0.8 standard deviations below average. Most were expected to reach their genetic target with continued growth.4PubMed. Final height in children with growth hormone deficiency In another cohort of 71 patients with various degrees of deficiency, mean final height was about 1.6 standard deviations below the population mean. A key finding was that final height correlated strongly with height at the onset of puberty, underscoring how much the timing of treatment matters.5PubMed. Final height in children with growth hormone deficiency
The takeaway from GH-deficient children is that treatment works, but outcomes fall on a spectrum. The kids who start earlier, before puberty erodes their remaining growth window, tend to do better. Those who enter puberty already behind have less time to catch up.
Results for Children Who Are Short but Not GH-Deficient
A more controversial use of growth hormone is in children with “idiopathic short stature,” meaning they are significantly short (typically below the first or third percentile for age) but produce normal amounts of growth hormone and have no identifiable medical reason for their short stature. The FDA approved growth hormone for this indication in the United States in 2003, but the gains are smaller and the debate over whether the benefit justifies the cost and commitment is ongoing.
A Cochrane review of growth hormone for idiopathic short stature found that one trial reported girls treated with growth hormone reached a near-final height about 7.5 cm taller than untreated controls. Other trials looking at shorter treatment periods found height gains ranging from none to roughly 0.7 standard deviations over a single year.6Cochrane Database of Systematic Reviews. Recombinant human growth hormone for idiopathic short stature in children A separate study of 88 children with idiopathic short stature reported more encouraging results: treated children reached an adult height that was, on average, about 9.5 cm taller for boys and 8.6 cm taller for girls compared to untreated controls.7PubMed Central. Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit
That spread in outcomes, from negligible to nearly 10 cm, reflects the reality that “idiopathic short stature” is a catch-all label covering many different underlying reasons for being short. Some of those children respond well, while others barely move the needle. Predicting who will benefit remains one of the field’s persistent challenges.
Turner Syndrome and Other Specific Conditions
Girls with Turner syndrome, a chromosomal condition affecting roughly 1 in 2,000 to 2,500 female births, are almost universally short. Without treatment, average adult height is typically around 143 to 147 cm. Growth hormone has been used for decades in this population, and the evidence for a meaningful height gain is solid.
A Canadian randomized controlled trial found that girls with Turner syndrome who received growth hormone were about 7.2 cm taller at the end of the study than controls. At follow-up a year or more later, the gap held steady at about 7.3 cm.8PubMed. Impact of growth hormone supplementation on adult height in turner syndrome: results of the Canadian randomized controlled trial A real-world study from India similarly showed that girls with Turner syndrome who received growth hormone experienced a clinically significant height gain, with the best outcomes tied to early diagnosis and early treatment initiation.9PubMed Central. Growth Hormone Treatment in Turner’s Syndrome: A Real World Experience
Growth hormone is also approved for children born small for gestational age who do not catch up in height by age two to four, and for certain genetic conditions like Prader-Willi syndrome and Noonan syndrome. In achondroplasia, the most common form of dwarfism, growth hormone alone produces modest gains, but combining it with surgical limb lengthening has yielded substantial increases in final height.10PubMed Central. Final adult height in long-term growth hormone-treated achondroplasia patients
What Determines How Much Height You Gain
Not every child who starts growth hormone therapy gets the same result. Several factors predict how well treatment works, and understanding them helps set realistic expectations.
The most consistent predictor is age at the start of treatment. Younger children have more years of open growth plates ahead of them, which gives the hormone more time to do its job. An analysis of children born small for gestational age found that growth hormone dose was the single strongest predictor of first-year growth response, accounting for about 35% of the variability. Age at treatment start was the second most important factor.11PubMed. Prediction of response to growth hormone treatment in short children born small for gestational age Midparental height (a rough genetic ceiling based on both parents’ heights) also matters: children with taller parents tend to respond more.
The practical implication is that waiting and hoping a child will catch up on their own carries a real trade-off. Every year of delay is a year of lost growth potential. At the same time, growth hormone is not a magic bullet. A child who starts treatment at 12 and enters puberty at 13 will gain far less than one who starts at 5 and has seven or eight more growing years ahead.
Getting Diagnosed Correctly
Before anyone is prescribed growth hormone, a proper diagnostic workup is essential. Growth hormone deficiency is confirmed through stimulation tests, where a provocative agent is given and blood levels of growth hormone are measured at intervals. A peak response below a certain threshold suggests the pituitary is not producing enough.12PubMed Central. Diagnosis and Treatment of Growth Hormone Deficiency: A Position Statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology
These tests are not perfect. A known pitfall involves children who are overweight or obese. Excess body fat blunts the growth hormone response on stimulation tests, which can make a child look GH-deficient when they are not. One study found that overweight and obese children had a false-positive rate on stimulation testing of about 25%, compared to roughly 9% in non-obese children. Integrating other markers like IGF-1 levels and growth velocity improved diagnostic accuracy, catching 9 out of 12 children who would have been misdiagnosed on the stimulation test alone.13PubMed Central. Obesity-Related Changes in Growth Hormone Stimulation Test Performance Under Pediatric Growth Hormone Deficiency If your child is being evaluated for growth hormone deficiency and is overweight, it is worth asking the endocrinologist how they account for this.
Combining Growth Hormone With Aromatase Inhibitors
Since estrogen is what ultimately shuts down the growth plates, researchers have explored whether blocking estrogen production could keep growth plates open longer and squeeze out additional height. Aromatase inhibitors, drugs that prevent the body from converting testosterone to estrogen, have been studied for this purpose in pubertal boys with idiopathic short stature.
A randomized trial compared aromatase inhibitors alone, growth hormone alone, and the combination in short pubertal boys. At 24 months, the combination group had gained about 18.9 cm in height, compared to 17.1 cm with growth hormone alone and 14.0 cm with aromatase inhibitors alone. At near-final height, boys who received the combination gained about 22.5 cm total, versus 20.6 cm with growth hormone alone.14PubMed Central. Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature A meta-analysis pooling several randomized trials confirmed that adding aromatase inhibitors to growth hormone yielded higher growth velocity, a younger bone age (meaning more remaining growth potential), and a predicted adult height about 5.5 cm greater than growth hormone alone.15PubMed Central. Aromatase inhibitors for short stature in male children and adolescents treated with growth hormone: a meta-analysis of randomized controlled trials
This combination approach is used almost exclusively in boys. In girls, blocking estrogen has broader hormonal consequences that make it a less practical option. And while the safety data from trials so far look reassuring, the approach is still considered off-label in most countries, meaning it is not a standard first-line recommendation.
Safety Concerns
Growth hormone therapy has been used in children since the 1980s, and the safety profile is generally considered favorable when the drug is used for approved indications at standard doses. Common side effects are relatively mild: joint pain, fluid retention, and occasionally headaches. The injection itself, given subcutaneously once daily (or once weekly with newer formulations), is the main source of discomfort for most children.
The bigger worry has always been cancer risk. Growth hormone promotes cell growth, and it is reasonable to ask whether that extends to abnormal cells. A comprehensive review of clinical and epidemiological studies found no clear evidence that growth hormone treatment causes cancer in the general pediatric population.16PubMed Central. Growth hormone treatment and risk of malignancy The one nuance involves childhood cancer survivors: some data suggest a small increased risk of developing a new cancer in this specific group, which is why oncology history is carefully weighed before starting treatment.
In adults treated with growth hormone for adult-onset deficiency, a large study tracking over 15,800 patients found that overall cancer rates were comparable to the general population. Patients with idiopathic or congenital deficiency actually had a lower-than-expected cancer rate.17The Journal of Clinical Endocrinology & Metabolism. Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients The evidence is reassuring, but ongoing monitoring during and after treatment remains standard practice.
The Cost Question
Growth hormone therapy is expensive. The drug itself typically costs tens of thousands of dollars per year, and treatment often continues for several years. For children with clear-cut growth hormone deficiency, most insurance plans cover it, though the approval process can be cumbersome. For idiopathic short stature, coverage is less consistent, and out-of-pocket costs can be prohibitive.
A cost-effectiveness analysis estimated that for children with idiopathic short stature, growth hormone treatment cost roughly $52,600 per additional inch of height gained, with an average incremental height gain of about 4.8 cm over five years of treatment and a total cost per child of about $100,000.18JAMA Pediatrics. Estimated Cost-effectiveness of Growth Hormone Therapy for Idiopathic Short Stature Whether that is “worth it” depends on whom you ask. For families, the calculus is deeply personal and involves weighing the psychological impact of short stature against the financial burden and daily injection regimen.
Newer long-acting formulations that require only weekly injections instead of daily ones are changing the treatment experience. An analysis from Ireland found that once-weekly somatrogon was associated with cost savings and a lower cost per centimeter gained compared to daily injections.19PubMed. Cost-effectiveness and cost-utility analysis of somatrogon once-weekly injections vs. daily growth hormone injection for treating paediatric growth hormone deficiency in Ireland Adherence also plays a role in cost-effectiveness: children who miss injections grow less per dollar spent. An Italian analysis found that using a connected injection device that tracked adherence and identified poor responders early resulted in patients gaining an average of 3.2 cm more than those on other delivery devices.20PubMed Central. Cost-consequence analysis for human recombinant growth hormone (r-hGH) treatment administered via different devices in children with growth hormone deficiency in Italy
Does Being Short Actually Cause Psychological Harm?
One of the arguments for treating short stature, especially in children who are not truly GH-deficient, is that being significantly shorter than peers causes psychological distress. The evidence here is more mixed than many assume.
A placebo-controlled trial found that after one year of blinded treatment, only the boys receiving real growth hormone (not placebo) showed improved height perception and reduced short-stature-related distress. Self-esteem also improved over longer-term open-label treatment.21PubMed. Growth hormone therapy and short stature-related distress: A randomized placebo-controlled trial However, a separate long-term placebo-controlled study found that short stature among children with idiopathic short stature was not associated with problems in psychological adaptation or self-concept on the measures used. Growth hormone treatment showed a trend toward fewer behavior problems as reported by parents, but the effects on quality of life and psychosocial function were not definitive.22PubMed. Psychological adaptation in children with idiopathic short stature treated with growth hormone or placebo
The picture that emerges is that some short children are genuinely distressed by their stature, and for them, the physical gains from growth hormone carry real psychological benefit. But the assumption that all short children suffer psychologically because of their height is not well supported. The decision to treat should involve a candid conversation about what the child actually experiences, not a blanket assumption that shorter equals unhappier.
Sleep, Exercise, and Natural Growth Hormone
Growth hormone is released naturally in pulses throughout the day, with the largest bursts occurring during deep sleep and during vigorous exercise.23PubMed. The exercise-induced growth hormone response in athletes This is the kernel of truth behind advice that children should get plenty of sleep and physical activity to grow well. For a child with a normally functioning pituitary gland, adequate sleep and regular exercise help ensure their growth hormone secretion is not blunted by lifestyle factors.
But it is important to be realistic about what these natural boosts can do. The transient spikes in growth hormone from a good night’s sleep or a hard workout are orders of magnitude smaller than the sustained pharmacological doses given in growth hormone therapy. For a child who is short because of genuine growth hormone deficiency or a genetic condition, no amount of sleep hygiene or exercise will compensate. These lifestyle habits support normal growth; they do not replace medical treatment when something is fundamentally wrong with the growth axis.
The supplement industry leans heavily on this natural-secretion angle, selling amino acid blends and herbal formulations that claim to “boost” growth hormone levels. Even when these products do produce a measurable bump in circulating growth hormone, the increase is brief and clinically insignificant for height. There is no evidence that any over-the-counter supplement adds meaningful stature, in children or adults. The gap between a brief hormonal blip and the sustained, high-dose exposure needed to drive bone growth is vast.